ARCT

Arcturus Therapeutics Holdings Inc. is a ribonucleic acid (RNA) medicines company focused on liver and respiratory diseases. In addition to its internal messenger RNA (mRNA) platform, its lipid nanoparticle deliver system, LUNAR, enables multiple nucleic acid medicines. It is expertized in the discovery and development of RNA medicines, including in the production of RNA drug substance and nanoparticle-formulated drug product. It has a pipeline of seven drugs in the late-stage discovery and early-stage development out of which two are wholly-owned and five are pharma partnered programs. It is focused on applying its technologies to develop RNA medicines in multiple therapeutic approaches, which include mRNA, deoxyribonucleic acid (DNA), and replicon protein replacement for therapeutics and protein delivery for vaccines; small interfering RNA (siRNA), microRNA, and antisense oligonucleotides knockdown of genes overexpressed in disease; and CRISPR, TALEN and zinc finger proteins.